Lead Product(s): K13
Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Yabao Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2015
Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.